A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

NCT07178171 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

TNBC, Triple Negative Breast Cancer

Interventions

DRUG: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
DRUG: Pirarubicin
DRUG: Nab-paclitaxel
DRUG: Carboplatin (AUC 5)
DRUG: Cyclophosphamide

Sponsor

Xijing Hospital

Collaborators

[object Object]